Ovidiu Virgil Maioru

Dr. Ovidiu Virgil Maioru

Medical Genetics, "Carol Davila" University of Medicine and Pharmacy,, Bucharest, Bucureşti, Romania
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OMOvidiu Virgil Maioru
Ovidiu Virgil Maioru
VRViorica Elena Radoi
Viorica Elena Radoi
MCMadalin-Codrut Coman
Madalin-Codrut Coman
IHIulian-Andrei Hotinceanu
Iulian-Andrei Hotinceanu
ADAndra Dan
Andra Dan
Emilia SeverinEmilia Severin
Emilia Severin
The purpose of this article is to highlight the new advancements in molecular and diagnostic genetic testing and to properly classify all ovarian cancers. In this article, we address statistics, histopathological classification, molecular pathways implicated in ovarian cancer, genetic screening panels, details about the genes, and also candidate genes. We hope to bring new information to the medical field so as to better prevent and diagnose ovarian cancer.

29 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
OMOvidiu Virgil Maioru
Ovidiu Virgil Maioru
VRViorica Elena Radoi
Viorica Elena Radoi
LBLaurenţiu-Camil Bohîltea
Laurenţiu-Camil Bohîltea
MCMadalin-Codrut Coman
Madalin-Codrut Coman
AEAnca-Elena Eftenoiu
Anca-Elena Eftenoiu
Emilia SeverinEmilia Severin
Emilia Severin
The purpose of this article is to highlight the new advancements in molecular and diagnostic genetic testing as well as properly classify all ovarian cancers. In this article we address statistics, histopathological classification, molecular pathways implicated in ovarian cancer, genetic screening panels and details about the genes, and also candidate genes. We hope to bring new information in the medical field as to better prevent and diagnose ovarian cancer.

29 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
VRViorica Elena Radoi
Viorica Elena Radoi
MȚMihaela Țurcan
Mihaela Țurcan
OMOvidiu Virgil Maioru
Ovidiu Virgil Maioru
ADAndra Dan
Andra Dan
LBLaurenţiu-Camil Bohîltea
Laurenţiu-Camil Bohîltea
ISIleana Delia Sabau
Ileana Delia Sabau
The Homologous Recombination Deficiency (HRD) Score, determined by evaluating genomic instability through the assessment of loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), serves as a crucial biomarker for identifying patients who might benefit from targeted therapies, such as PARP inhibitors (PARPi). This study aimed to investigate the efficacy of HRD testing in high-grade serous ovarian carcinoma, tubal, and peritoneal cancer patients who are negative for somatic BRCA1 and BRCA2 mutations and to evaluate the impact of HRD status on Bevacizumab and PARPi therapy response. A cohort of 100 Romanian female patients, aged 42–77, was initially selected. Among them, 30 patients had unsuitable samples for HRD testing due to insufficient tumor content or DNA integrity. Using the OncoScan C.N.V. platform, HRD testing was successfully performed on the remaining 70 patients, with 20 testing negative and 50 testing positive for HRD. Among the HRD-positive patients, 35 were eligible for and benefited from PARPi maintenance therapy, resulting in a median progression-free survival (PFS) increase from 4 months to 8.2 months. Our findings support the importance of HRD testing in ovarian cancer patients, demonstrating the potential therapeutic advantage of PARPi therapy in HRD-positive patients without somatic BRCA1/2 mutations.

Verified
Journal Article
Open access
PDF file
ISIleana Delia Sabau
Ileana Delia Sabau
LBLaurenţiu-Camil Bohîltea
Laurenţiu-Camil Bohîltea
VRViorica Elena Radoi
Viorica Elena Radoi
ABAnca Mirela Bardan
Anca Mirela Bardan
OMOvidiu Virgil Maioru
Ovidiu Virgil Maioru
Iuliana CeausuIuliana Ceausu
Iuliana Ceausu
One major cause of prenatal mortality and morbidity is congenital abnormalities. Knowing the prevalence and etiology of congenital malformations is essential for analyzing trends and improving neonatal care. Objective: the team aimed to evaluate the utility of whole-exome sequencing (WES) in Romanian prenatal care, highlighting its diagnostic efficacy in comparison to molecular karyotyping, particularly in cases with negative genetic results prior to WES, unfavorable pregnancy outcomes, and consanguinity. Methods: Initially, we identified pregnancies with abnormal ultrasounds unrelated to known syndromes. Subsequently, we performed SNP (single nucleotide polymorphism)-array testing, yielding negative results. We then applied prenatal WES, utilizing Massive Parallel Sequencing on the NovaSeq 6000 platform (average coverage > 100× read length: 2 × 100 bp) with library preparation using the Twist Human Core Exome kit RefSeq & Mitochondrial panel (Twist Bioscience). The bioinformatic analysis involved direct comparison to the human reference sequence (hg38). Results: We achieved a 50% diagnostic rate. After receiving results, two couples chose pregnancy termination, five had uneventful births, and one pregnancy ended in stillbirth. Additionally, we identified three incidental findings that enhanced patient and at-risk member management. This article details ten prenatal cases tested with WES, highlighting its superior diagnostic performance compared to the SNP array. WES detected the genetic diagnostic in 50% of cases that the SNP array did not. We emphasize the advantages of WES in prenatal diagnostics while acknowledging the need for further investigations to comprehensively evaluate its diagnostic utility in the Romanian population.

1 July 2023 in Revista Romana de Medicina de Laborator
Verified
Journal Article
Open access
PDF file
VRViorica-Elena Radoi
Viorica-Elena Radoi
LPLucian pop
Lucian pop
OMOvidiu Virgil Maioru
Ovidiu Virgil Maioru
DSDelia Sabau
Delia Sabau
ADAndra Dan
Andra Dan
LBLaurentiu-Camil Bohiltea
Laurentiu-Camil Bohiltea
Introduction: Cancer is the leading cause of death and an important impediment to increasing life expectancy in every country of the world. During the process of oncogenesis, genetic and epigenetic changes lead to abnormal expression of genes associated with cellular pathways that coordinate extremely important functions such as cell multiplication, cell differentiation, cell death, and cell cycle. Methods: There are over 200 approved biomarker-driven drugs for various types of cancer. Valuable biomarkers are analyzed to establish their importance in specific therapies. Precision medicine for oncological patients has been recognized as a valuable approach to solid tumors. Results: Various genes and their mutations either have a direct pathogenic effect or can give hints to a certain prognosis regarding the oncological pathology. A comprehensive genetic test for a broad molecular profile and complete characterization of tumor genetic heterogenicity should contain genes that are aligned with professional practice, guidelines and clinical trials, full coding region coverage for each gene and targeting of unique emerging and actionable markers. It is useful to use such a comprehensive test when a broad genomic profile identifies treatment options including immunotherapies and targeted drugs for patient enrollment or when relapse or disease progression has occurred after prior therapies. Conclusions: For patients

20 June 2022 in Romanian Medical Journal
Verified
Journal Article
Open access
OMOvidiu Virgil Maioru
Ovidiu Virgil Maioru
LPLucian Pop
Lucian Pop
VRViorica Radoi
Viorica Radoi
RURadu Ursu
Radu Ursu
Nicolae BacalbaşaNicolae Bacalbaşa
Nicolae Bacalbaşa
ISIoan D. Suciu
Ioan D. Suciu